Mr. Fergal Goodman:

Ireland is involved in the process with the European Commission where the option for us is to either go with the terms of the agreements that have been negotiated between the Commission and each company, or not. That is a difficult call in the sense that it means the terms of the indemnities the companies have sought, in the context of the rapid development of these products, is a call on which Ireland as an individual State does not have much choice if I am honest. That is the situation on that. I am not aware of the general proposition in relation to vaccines. I believe it is these ones in particular.